News for Atara Biotherapeutics, Inc. (ATRA)

Key Highlights: Atara Biotherapeutics' (ATRA) shares surged 7% following FDA priority review for its Tabelecleucel treatment. Analysts project a favorabl

Atara Biotherapeutics (ATRA), in partnership with Pierre Fabre Pharmaceuticals (PFP), has announced that the FDA has accepted their Biologics License Applicatio

Atara Biotherapeutics (ATRA) has received U.S. FDA acceptance for the Biologics License Application (BLA) of tabelecleucel (Tab-cel®). The application

Atara Biotherapeutics Inc. (ATRA) is one step closer to securing approval for Tabelecleucel, a first-of-its-kind treatment for patients in the U.S..

BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. ( IKNA) (”œIkena”) and Inmagene Biopharmaceuticals (”œInmagene”) today anno

BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) ('Ikena”) and Inmagene Biopharmaceuticals ('Inmagene”) today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ('Imagene”), of the combined company after the anticipated closing.

Key Takeaways: Panacea Innovation Ltd. increases its stake in Atara Biotherapeutics to 23% with a significant share purchase. Analysts offer a bullish on

Pierre Fabre Pharmaceuticals now manages global clinical trials for tabelecleucel following IND transfer from Atara Biotherapeutics (ATRA). Tabelecleuce

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

Atara Biotherapeutics (ATRA) has resubmitted a Biologics License Application (BLA) for tabelecleucel (tab-cel®) to the U.S. FDA. FDA approval could tri

On May 16, 2025, Redmile Group, LLC (Trades, Portfolio) executed a notable transaction involving Atara Biotherapeutics Inc. The firm added 263,506 shares of Ata

Atara Biotherapeutics (ATRA) has expanded its Board of Directors by appointing James Huang and Nachi Subramanian. This development follows the successful conclu

Atara Biotherapeutics (ATRA) adds James Huang and Nachi Subramanian to its Board of Directors. The appointments follow Atara's recent $16 million offeri

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to devel

Key Highlights: Atara Biotherapeutics announces a new share offering set to raise $16 million. Analysts forecast a potential upside of 131.97% from the c

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to devel

Atara Biotherapeutics, Inc. (ATRA) announces a $16 million offering of common stock and pre-funded warrants. The offering consists of 834,237 shares at

[url="]Atara Biotherapeutics, Inc.[/url] (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell plat